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 54 
Abstract 55 
Context: Larger studies on outcomes in males with 45,X/46,XY mosaicism are rare. 56 
Objective: To compare health outcomes in males with 45,X/46,XY diagnosed due to either genital 57 
abnormalities at birth or non-genital reasons later in life. 58 
Design: A retrospective, multicenter study 59 
Setting: 16 tertiary centers 60 
Patients or other participants: 63 males older than 13 years with 45,X/46,XY mosaicism. 61 
Intervention(s): None. 62 
Main Outcome Measure(s): Health outcomes such as genital phenotype, gonadal function, 63 
growth, comorbidities, fertility, and gonadal histology including risk of neoplasia. 64 
Results: 35 patients were in the genital group, 28 in the non-genital. 80% of all patients 65 
experienced spontaneous pubertal onset, significantly more in the non-genital group (p = 0.023). 66 
Patients were significantly shorter in the genital group with median adult heights of 156.7 cm and 67 
164.5 cm, respectively (p = 0.016). 27% of patients received recombinant human growth hormone. 68 
44 patients had gonadal histology evaluated. Germ cells were detected in 42%. Neoplasia in situ 69 
was found in five patients. 25% had focal spermatogenesis, another 25.0% had arrested 70 
spermatogenesis. 14 out of 17 (82%) with semen analyses were azoospermic; three had motile 71 
sperm. 72 
Conclusion: Patients diagnosed due to genital abnormalities have poorer health outcomes than 73 
those diagnosed due to non-genital reasons. Most patients, however, have relatively good 74 
endocrine gonadal function, but most are also short statured. Patients have a risk of gonadal 75 
neoplasia and most are azoospermic, but almost half of patients have germ cells present 76 
histologically and up to a quarter have focal spermatogenesis, providing hope for fertility 77 
treatment options.  78 
 79 
 80 
81 
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Introduction 82 
45,X/46,XY mosaicism and its variants are rare with a previously reported incidence of 1/15,000 live 83 
births (1). The resulting phenotype spans across a wide range of effects including genital anomalies, 84 
impaired growth, altered gonadal function and histology, and infertility. The karyotype is covered 85 
by the umbrella term Differences (or Disorders) of Sex Development referring to diagnoses in which 86 
anatomical, gonadal and/or chromosomal sex are affected (2). The 45,X cell line in these patients 87 
probably stems from the loss of a normal or structurally abnormal Y-chromosome in early 88 
embryonic mitosis, which produces the mosaicism (3–7). 89 
 90 
The phenotypic spectrum of 45,X/46,XY patients varies greatly from females with Turner syndrome 91 
to normally androgenized males. Moreover, several studies have reported that 80-95% of prenatally 92 
diagnosed cases with a 45,X/46,XY karyotype are born as normally androgenized males (3,5,8,9), 93 
whereas postnatally diagnosed pediatric cases present more varied phenotypes including 94 
ambiguous genitalia (5,10,11). Furthermore, normally androgenized male patients with a 95 
45,X/46,XY karyotype diagnosed in adulthood are now more frequently identified due to male 96 
infertility work-ups, including genetic screening (12). Thus, severity of the patient’s phenotype often 97 
appears to be directly related to the age at diagnosis and reason for referral.  98 
 99 
The wide spectrum of phenotypes in these patients is also reflected in health outcomes such as 100 
growth, gonadal function, risk of gonadal neoplasia and comorbidities that are all reported with 101 
varying incidences and severities both within the same centers and between centers (5,7,10,13–16). 102 
It seems intuitive that the severity of the genital phenotype may be considered a read-out for other 103 
health outcomes. Nevertheless, even normally androgenized males diagnosed in adulthood have 104 
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been reported to have short stature, declining testicular function with age and infertility, likely 105 
related to histologically dysgenetic testes (5,6). However, there is a lack of studies with direct 106 
comparisons of outcomes in terms of growth, gonadal function and comorbidities between patients 107 
diagnosed at birth due to genital abnormalities and those diagnosed later in life due to other reasons 108 
such as short stature, pubertal delay and infertility. 109 
 110 
The risk of gonadal neoplasia in patients with 45,X/46,XY mosaicism is reported to be relatively high 111 
at around 10-15% (5,16–19). The current practice of early (prepubertal) gonadectomy in girls 112 
renders it impossible to evaluate gonadal function and possible fertility potential in women. 113 
Moreover, single-center studies on histological outcomes are limited by numbers thus making 114 
thorough pathohistological evaluations of larger datasets rare.  115 
 116 
Thus, we wanted to investigate and compare health outcomes such as growth, gonadal function, 117 
comorbidities, fertility and histology including risk of neoplasia in males with 45,X/46,XY mosaicism 118 
and variants diagnosed due to different reasons 1) genital abnormalities and 2) other reasons such 119 
as stunted growth, lack of pubertal onset, undervirilization and infertility in a large multicenter study 120 
with 16 participating centers including a total of 63 male patients with 45,X/46,XY mosaicism.  121 
 122 
Materials and Methods 123 
 124 
Subjects 125 
Patients were identified using the I-DSD Registry, which contains pseudoanonymized information 126 
on patients with DSD. Information on the registry is available at 127 
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https://www.gla.ac.uk/schools/medicine/research/childhealth/researchinterests/i-dsdproject/ 128 
and recent uses of the registry have previously been published (14,20). 129 
We identified centers in the registry that had included patients with 45,X/46,XY and its variants 130 
(including different aberrations to the Y-chromosome such as deletions and isodicentricism, and a 131 
single patient with a 45,X/46,XX(SRY-pos) karyotype) uploaded to the registry. Through the COST 132 
network DSDnet (http://www.dsdnet.eu/cost.html), three additional centers with patients not yet 133 
uploaded to the registry were identified. A total of 22 centers were contacted, of which 19 centers 134 
responded, and 16 centers supplied data on a total of 63 male patients. The inclusion criteria were: 135 
male gender of rearing and an age old enough to evaluate height and gonadal function (>13 years 136 
of age). 137 
 138 
Patients were stratified into two groups according to whether they were diagnosed due to genital 139 
abnormalities or other reasons (hereafter ‘genital’ and ‘non-genital’, respectively). Other reasons 140 
included prenatal screening (fetal and maternal factors), growth retardation, gynecomastia, lack of 141 
spontaneous pubertal onset, lack of virilization in adulthood and infertility. Two patients in the non-142 
genital group underwent hypospadias repairs and thus had genital abnormalities but were not 143 
diagnosed due to these and were thus included in the non-genital group. 144 
 145 
Data collection 146 
Following identification of suitable cases in the I-DSD Registry, each center was contacted to 147 
complete a detailed questionnaire that collected the following information: age at presentation, 148 
reason for diagnosis, karyotype, sex of rearing, birth weight and length, genital phenotype including 149 
External Masculinization Score (EMS, as described by Ahmed et al (21)), renal and cardiac 150 
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comorbidities, growth including target height and recombinant human Growth Hormone (rhGH) 151 
treatment, pubertal onset, gynecomastia, testosterone (T) treatment, genital and gonadal surgery, 152 
gonadal histology including neoplasia, fertility workups, and endocrine biochemistry at presentation 153 
and at last available follow-up. Histopathological evaluations were translated locally and added to 154 
a predefined table by each participating center. In a few cases attempts were made to get further 155 
evaluations, images and/or tissue blocks. However, this was not always possible. Thus, an image of 156 
a gonadoblastoma from a patient not included in this study (with a 46,XX/47,XYY/48,XXYY karyotype 157 
from the biobank at Dept. of Growth and Reproduction, Copenhagen) is used. 158 
 159 
Hormone assays 160 
Sixteen centers participated in this study and different commercially available assays were used to 161 
measure follicle-stimulating hormone (FSH), luteinizing hormone (LH) and testosterone (T). All FSH 162 
and LH concentrations were reported using IU/L. T concentrations were reported in nmol/L, ng/mL 163 
and pg/mL. Based on the molar mass of T of 288 Daltons, all values were standardized to nmol/L 164 
(nmol/L = ng/mL x 3.47 mol/L). Reference ranges for FSH and LH were based on measurements using 165 
the time-resolved immunoflourometric assays (Delfia; PerkinElmer, Boston, MA). The limits of 166 
detection (LODs) were 0.05 and 0.05 IU/L, respectively. The intra- and interassay coefficients of 167 
variation (CVs) were <5% in both assays. Reference range values for T were measured using the DPC 168 
Coat-A-Count RIA kit (Diagnostic Products Corp). LOD was 0.23 nmol/L. Intra- and interassay CVs 169 
were 7.6% and 8.6%, respectively. Due to the retrospective and historic nature of the study, assay 170 
details were not available from all participating centers. 171 
 172 
Hormone reference ranges 173 
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Reference ranges and LODs plotted were based on the assays used at the Department of Growth 174 
and Reproduction, Copenhagen University Hospital, Copenhagen, Denmark, where this study was 175 
based. Any values below the LODs were plotted as (LOD/2). All reference ranges of reproductive 176 
hormones and testicular volumes are based on a total of 2095 healthy boys recruited for a cross-177 
sectional study of healthy, Danish children (The Copenhagen Puberty Study) as previously published 178 
(22,23). Plotting the reference ranges, despite being from a single center only, was done to enable 179 
comparison of normative data and the patient data. 180 
 181 
Statistical analyses  182 
The genital and non-genital groups were compared using the Mann-Whitney U test in terms of 183 
external genitalia (EMS), age at referral, final height and height SD scores, while Pearson’s Chi-184 
Squared or Fischer’s Exact Test (wherever appropriate) was used to compare the binary outcomes 185 
of spontaneous puberty, renal and cardiac malformations and disease, genital and gonadal 186 
surgeries, fertility, gonadal neoplasia, spermatogenesis, presence of germ cells and distribution 187 
(presence) of testicles and streak gonads.  188 
Height was standardized using height-for-age standard deviation scores and plotted against 189 
reference ranges from the World Health Organization (WHO) (24).  190 
 191 
Ethical considerations 192 
The I-DSD registry is approved by the National Research Ethics Service of the United Kingdom for 193 
collection of routine clinical data. In addition, each center obtained necessary approvals and 194 
adhered to local laws regarding data collection from patient files. Patient and/or parental consent 195 
was obtained prior to registration of cases in the I-DSD Registry. The database from this study is 196 
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based in Copenhagen, Denmark, and has received appropriated approvals from the Danish Data 197 
Protection Agency (RH-2015-235, I-Suite no.: 04204) and the Danish Health and Medicinal 198 
Authorities (3-3013-1376/1). COPENHAGEN Puberty Study was approved by the Danish Data 199 
Protection Agency (2015-41-4494) and by the regional ethics committee (KF 01 282214 and 200 
V200.1996/90).  201 
 202 
Results 203 
 204 
In total, 63 males from 16 different centers were included in this study. All patients had missing 205 
values for one or more variables, but all were included in the study. 206 
 207 
Age and phenotype at diagnosis 208 
Thirty-five (55.6 %) patients were diagnosed due to genital abnormalities and 28 (44.4%) were 209 
diagnosed due to other reasons. Ages at first presentation were (median (range)) 0.0 years (0.0-42.7 210 
years) and 24.0 years (0.0 to 49.0 years) in the two groups (n=34 genital, 27 non-genital), 211 
respectively (Table 1). 212 
EMS scores at first examination were (median (range)) 4.0 (1.0 to 9.5) and 12.0 (10.0 to 12.0) in each 213 
group, respectively (n=24 genital, 20 non-genital) Table 1), and significantly differed between the 214 
groups (p<0.001). 215 
 216 
The prevalence of hypospadias repairs (p<0.001), orchidopexies (p=0.006) and gonadectomies 217 
(p<0.001) was higher in the genital group (Table 1). 218 
 219 
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Spontaneous puberty, reproductive hormones and T replacement  220 
The majority of patients in both groups entered puberty spontaneously (n=47 patients (79.7%)) with 221 
a significantly higher prevalence in the non-genital group (n=22 genital, 25 non-genital, p=0.023, 222 
Table 1). Twenty-one patients (39.6%) were treated with T at some point or continuously during the 223 
follow-up period with significantly more in the genital group (17 genital, 4 non-genital, p=0.013). 224 
Regardless of the reason for diagnosis, most patients had FSH and LH concentrations at the higher 225 
end of the normal reference range (Fig. 1). Likewise, T levels were mostly within the normal 226 
reference range. Testicular volumes were typically normal or low within the reference range 227 
independent of diagnosis group (Fig. 1).  228 
 229 
Growth 230 
Final heights were reduced in the genital compared to the non-genital group (median (range) 156.7 231 
cm (143.0-169.2 cm) and 164.5 cm (141.1-187.7 cm, p=0.001) (Table 1 and Fig. 2a). However, when 232 
the genetic potential was accounted for there was no significant difference. Patients in neither 233 
group grew according to genetic potential (height SDS – target height SDS) (median SDS (range)): -234 
2.5 (-4.2 to -1.2) and -2.2 (-3.4 to -1.0) (Table 1 and Fig. 2b).  235 
 236 
Seventeen patients (27.0%) were treated with rhGH with no significant difference in the number of 237 
treated patients between the two groups (p=0.066). There was no difference in height SD scores 1 238 
year prior to and 1 or 5 years following treatment for all patients overall and when subdivided into 239 
the two diagnosis groups or grouped based on treatment (no treatment vs. treated) (all p > 0.05) 240 
(Fig 2c).  241 
 242 
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Comorbidities 243 
Cardiac malformations were more frequent (13 patients, 22.4%) than renal malformations (seven 244 
patients, (12.3%)) (Table 1). There was no difference in frequencies between the groups. 245 
 246 
Gonadal histology, spermatogenesis and neoplasia 247 
Histological features from gonadal biopsies and/or gonadectomies from 44 patients (65.0%), 248 
including a total of 61 gonads are summarized in Table 2 and Fig. 3-4. In total, 31 patients from the 249 
genital group (88.6%) and 13 from the non-genital group (46.4%) had histological data available.   250 
Patients either had bilateral testicular tissue (51.2%, 10 genital, 11 non-genital) or testicular tissue 251 
on one side and more undifferentiated ovarian-like tissue on the contralateral side, most often in 252 
the form of streak gonads (48.8%, 18 genital, 2 non-genital) (Fig. 3-4).  253 
Sertoli-cell only pattern was evident in 30 patients with available pre- and/or postpubertal 254 
histological samples (SCO) (66%). In seven of the post-pubertal patients (35%), the SCO pattern was 255 
also associated with spermatocytic arrest in other tubules and in a single case with tubules 256 
containing GCNIS (Tables 2-3). 257 
 258 
Germ cells were detected in 42.1% of patients (9 genital, 7 non-genital), whereas no germ cells were 259 
found in 55.3% of patients (15 genital, 6 non-genital). Seven patients did not have information on 260 
germ cells available. There was no significant difference between ages at biopsy/gonadectomy in 261 
patients with detectable germ cells and patients without detectable germ cells (median (range), 262 
18.77 years (0.10 to 49.40) vs. 13.55 years (0.30 to 47.50), p = 0.154). 263 
 264 
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Folliculogenesis was not detected in any of the included gonadal samples. Moreover, three patients 265 
were originally labelled with ovotestes but upon thorough re-examination of the original slides, no 266 
follicles could be detected and therefore the presence of ovotestes could not be confirmed in any 267 
of the samples from the present study.  268 
 269 
Spermatogenesis was evaluated by histology in 20 post-pubertal patients. Spermatids were present 270 
in 25.0% (2 genital, 3 non-genital), while in 50.0% (6 genital, 4 non-genital) no germ cells were 271 
observed (Fig. 3). In the remaining 25.0%, germ cells were present, but with arrest of 272 
spermatogenesis at different stages. The five patients with spermatids present had a median EMS 273 
score of 11.5 (4.0 to 12.0) (Table 2). 274 
 275 
Germ cell neoplasia in situ (GCNIS) was present in four patients (two prepubertal, two post-pubertal) 276 
and gonadoblastoma in one (total n=5, 11.4%, 4 genital, 1 non-genital) (Tables 1 and 2). The median 277 
EMS score in these patients was 4.8 (1.0 to 12.0) (Table 2).  278 
Tubules with preserved spermatogenesis, including presence of spermatids were present alongside 279 
tubules with GCNIS in both of the post-pubertal patients (one patient with an EMS of 4, one patient 280 
with an EMS of 12).  281 
 282 
Overall, when comparing the included histology parameters between the genital and the non-283 
genital groups, no differences were found (all p>0.05), except for a significant difference in the 284 
distribution of predominantly male only and mixed gonads in the two groups with predominantly 285 
male gonads being more frequent in the non-genital group (p = 0.009). 286 
 287 
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Fertility 288 
Complete azoospermia was observed in 14 (82.4%, 2 genital, 12 non-genital) of 17 patients who had 289 
undergone clinical semen analyses (Table 4). Three (17.6%, 1 genital, 2 non-genital) had evidence 290 
of live spermatozoa (one sample with some live spermatozoa, one sample with a concentration of 291 
0.06 million/mL and few progressively motile, and lastly one small volume sample with a 292 
concentration of 114 million/mL). In all of these three cases, spermatids had also been identified in 293 
the histological evaluation. One azoospermic patient had spermatids present in a histological 294 
sample (Table 4). 295 
 296 
One of the three patients with live spermatozoa in their semen sample underwent testicular sperm 297 
cell extraction during orchiectomy following a biopsy showing GCNIS. However, none of the patients 298 
included in this study fathered biological offspring during the follow-up period.  299 
There was no significant difference in fertility (azoospermia vs. live spermatozoa) between the 300 
genital and non-genital groups (p = 0.42). 301 
 302 
Discussion 303 
 304 
This large, multicenter study of male patients with 45,X/46,XY mosaicism found that most patients 305 
are short with varying degrees of gonadal function. Moreover, gonadal histology revealed that the 306 
risk of pre-neoplasia was relatively high, but also that the presence of ongoing spermatogenesis was 307 
common. Lastly, the risk of pre-neoplasia and presence of spermatogenesis appear to be 308 
independent of genital phenotype (degree of virilization).  309 
 310 
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In general, almost 80% of males with 45,X/46,XY mosaicism had sufficient gonadal function to enter 311 
puberty spontaneously, although almost 40% needed subsequent T treatment. However, patients 312 
in the genital group had lower rates of spontaneous puberty and higher rates of T treatment. 313 
Interestingly, we found that most of the patients appeared to have normal serum concentrations of 314 
T. It has previously been reported that many patients with scrotal gonads have some hormone 315 
production (25), but it was unexpected that most patients had T levels in the normal range despite 316 
their genital phenotype and overall fairly small testicular volumes. However, gonadotropin levels 317 
were relatively high indicative of some degree of (early) gonadal failure. Altogether, our findings are 318 
in accordance with previous reports on gonadal function in males with a 45,X/46,XY karyotype 319 
(5,7,10,16,26).  320 
 321 
Most patients in this cohort were short and did not grow according to their genetic potential. 322 
Patients in the genital group were significantly shorter than those in the non-genital, probably 323 
reflecting that patients with more severe genital phenotypes (genital group) are also more likely to 324 
have affected growth. This could in theory be due to a larger degree of 45,X cells and thus a larger 325 
degree of SHOX-haploinsufficiency as seen in classic Turner syndrome. Some of the growth 326 
trajectories in the adolescent patients in this study appeared to lack the expected pubertal growth 327 
spurt. Theoretically, hypogonadism in adolescence could potentiate the effects of the 45,X cell line 328 
on growth (5–7,10,15,27,28), thus producing this growth pattern. It is noteworthy that a recent 329 
study reports that XY-mosaic Turner patients have less affected growth than classic Turner girls (29)- 330 
 331 
One third of patients in this study received rhGH treatment, and the percentage was not influenced 332 
by group. Final height SD scores were similar in groups with and without rhGH treatment, but the 333 
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retrospective nature of this study does not allow firm conclusions on the efficacy of rhGH treatment. 334 
In general, the literature shows contradictory findings on the effects of rhGH treatment on growth 335 
(30), and our results as well as those from previous studies raise the critical need for well-designed 336 
studies to examine the possible benefits of rhGH in these children. However, none of the existing 337 
studies are randomized controlled trials and the opposing results could be due to study design and 338 
perhaps also the underlying mechanisms of the growth retardation.  339 
 340 
Theoretically, earlier intervention could improve several of the aforementioned clinical outcomes 341 
compared to patients with delayed or no intervention. However, a conclusive study will require a 342 
larger sample size as well as detailed information on T therapy. 343 
 344 
The vast histological material in this study (44 patients, 61 gonads) showed a broad phenotypic 345 
spectrum confirming that some patients had one (often scrotal) testis and one intraabdominal 346 
streak gonad (48.8%), while others had two testes (often bilaterally scrotal) (51.2%). The distribution 347 
was significantly different between the genital and non-genital groups. The 45,X/46,XY karyotype 348 
alone therefore does not allude to the histology nor the location of the gonads, and thus, applying 349 
the term “mixed gonadal dysgenesis” to this patient population could be deemed as inappropriate. 350 
 351 
Most gonads in this study were dysgenetic testes but there was a wide range from relatively normal 352 
testes containing tubules with complete/full spermatogenesis to streak gonads at each end of the 353 
spectrum. We did not detect the presence of follicles in any of the gonad samples evaluated. This 354 
could be due to oogonial loss prior to the formation of primordial follicles or breakdown of formed 355 
follicles already in early (fetal) life. Consensus understanding is that it takes two X chromosomes for 356 
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primordial follicles to develop. This notion is supported by a study examining the presence of 357 
primordial follicles (and number of germ cells) in ovaries from Turner fetuses aged 17-37 weeks, 358 
which reported that no primordial follicles could be detected (31). The etiology behind the 359 
45,X/46,XY karyotype has been suggested as one where larger, structural aberrations such as 360 
deletions, isodicentricism etc. or minor molecular abnormalities to the Y-chromosome may cause 361 
its loss in some cells (3–7). Thus it appears plausible that the vast majority of patients with 362 
45,X/46,XY mosaicism never have had two X chromosomes present and the development of follicles 363 
therefore seems unlikely, supported by our current findings. Moreover, it has previously been 364 
reported that gonads are relatively often mislabeled as ovotestes in 45,X/46,XY patients (32). The 365 
morphology in these samples resembles undifferentiated gonadal tissue and/or streak-like tissue 366 
with scattered germ cells. In such cases a higher risk of neoplasia, namely gonadoblastoma instead 367 
of GCNIS, has been reported (33). Given all of the above, it seems possible that ovotesticular DSD in 368 
45,X/46,XY patients is a rarity, or maybe even a misconception, as has also previously been 369 
suggested (32). Additionally, regarding future fertility preservation potential, the focus should lie on 370 
spermatogenesis rather than folliculogenesis in these patients.  371 
 372 
In 11.4% of patients we found gonadal neoplasia, specifically four patients with GCNIS and one 373 
patient with gonadoblastoma. Given the majority of (dysgenetic) testes in this series, GCNIS is the 374 
more likely neoplasia in this group of patients, which is in line with previous reports of 375 
gonadoblastoma being more frequent in patients with 45,X/46,XY mosaicism raised as females (18). 376 
Interestingly, we found that both post-pubertal patients with GCNIS had spermatogenesis alongside 377 
their neoplasia. This is a very important point for clinicians since testicular sperm cell extraction or 378 
aspiration should be considered before gonadectomy in these patients, as was done in one patient 379 
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in this study. It also indicates that the presence of spermatogenesis should not be interpreted as 380 
absence of testicular dysgenesis, and also poses the question of when to biopsy post-pubertal 381 
patients in particular. 382 
 383 
Interestingly, there did not appear to be a correlation between EMS and risk of germ cell malignancy. 384 
A higher risk of neoplasia has previously been found in patients with greater genital ambiguity 385 
(5,16), but our current findings are not completely in accordance with this notion. This may be 386 
explained by the fact that the study population of this study differs from previous studies, with only 387 
men and not females with a Turner syndrome phenotype included. It probably also highlights a dual 388 
relationship in which severely dysgenetic gonads do not sufficiently support germ cells regardless 389 
of whether these are normal or potentially malignant. Conversely, a low EMS score in men with 390 
45,X/46,XY mosaicism is highly suggestive of dysgenetic testes or undifferentiated gonadal tissue 391 
which if germ cells are present has a high risk of GCNIS. Thus, clinicians should be aware of the risk 392 
of malignant germ cells in all patients regardless of virilization status. 393 
 394 
Surprisingly, a quarter of post-pubertal patients had focal spermatogenesis, while another quarter 395 
had spermatogenesis arrested at different stages of germ cell differentiation. Altogether this 396 
demonstrates a future fertility potential in up to half of the post-pubertal patients. It was 397 
noteworthy that many patients demonstrated focal SCO along with spermatocytic arrest at different 398 
stages highlighting that each gonad may be heterogenous and focal spermatogenesis cannot be 399 
ruled out based on a single biopsy. Moreover, one azoospermic male had histological evidence of 400 
spermatids emphasizing that even males with azoospermia may have focal spermatogenesis. 401 
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The implications of the high proportion of patients with spermatogenesis and spermatocytic arrest 402 
are important; in vitro spermatogenesis, in which germ cells are differentiated in vitro, may provide 403 
a future fertility treatment option for these patients. However, no verified protocol is currently 404 
available for human testis tissue despite few previous reports of successful in vitro maturation of 405 
germ cells in human tissue (34–37) and even early-stage germ cells (prepubertal) in mice (38). The 406 
possibility that a protocol for human in vitro spermatogenesis may be established in the near future 407 
also raises the question of whether attempts to cryopreserve testicular tissue from 45,X/46,XY 408 
patients should be considered. It does, nonetheless, also provide the clinician with ethical dilemmas 409 
such as including patients in experimental protocols where the outcome and timeline is still 410 
unknown (current patients may not benefit), as well as possible transmission of an aberrant Y 411 
chromosome to offspring.  412 
 413 
No patients fathered offspring during the follow-up period and over 80% had complete azoospermia 414 
(assessed by their semen samples). However, almost 20% did produce semen samples with live 415 
spermatozoa. Both findings are in accordance with previous studies reporting low or no fertility in 416 
patients with 45,X/46,XY mosaicism (6,12,26,39). It is important to note that the males with live 417 
spermatozoa in this study were diagnosed at different ages from birth into adulthood and with 418 
varying degrees of genital androgenization. Clinicians should therefore be aware of fertility 419 
preservation methods, also in the pediatric setting, and semen sampling should be considered in all 420 
patients once they enter a mature age in late adolescence or early adulthood. 421 
 422 
The strengths of this study include: 1) the multicenter design which has made it possible to collect 423 
data on a large series of males 2) the inclusion of numerous outcomes in a single study, both clinical 424 
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and histological, which allows for a thorough understanding of the outcomes and how they relate 425 
(or do not) to gonadal histology and karyotypic etiology 3) all patients are old enough to have long-426 
term outcomes such as gonadal function and final height assessed 4) all patients are raised as males 427 
allowing for a unified evaluation of their outcomes. There are, however, also limitations and they 428 
include: 1) the retrospective design which has led to missing data for some variables for all patients 429 
2) histological data was not available in all patients and conclusions may be skewed by the fact that 430 
the most severely affected individuals are far more likely to have gonadal biopsies 3) the use of 431 
reference ranges for LH, FSH, T, testicular volumes and growth based on a Danish population and 432 
the WHO growth curves, respectively, which do not reflect the composition of this study population, 433 
although allowing for the comparison of healthy backgrounds populations with the patients studied 434 
4) some of the patients included in this study have been included in studies previously published 435 
(5,16,27) which may alter conclusions if drawn across published data 5) most patients were 436 
diagnosed post-pubertally which may skew conclusions towards poorer outcomes than if they had 437 
been prenatally diagnosed 6) patients were followed at multiple centers and consequently follow 438 
up schemes varied considerably. 439 
 440 
In conclusion, in this large, multicenter study of males with 45,X/46,XY mosaicism, we find that 441 
patients diagnosed due to genital abnormalities have poorer health outcomes than those diagnosed 442 
due to other reasons such as short stature, lack of puberty, and infertility. Overall, patients do, 443 
however, have relatively good endocrine gonadal function, but most are also short statured. 444 
Moreover, patients regardless of reason for referral have a relatively high risk of gonadal neoplasia 445 
and most are azoospermic. Nevertheless, almost half of patients have germ cells present, and up to 446 
a quarter have focal spermatogenesis which provides hope for fertility treatment in some patients 447 
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and future treatment options in many. In general, the data indicates the importance of highly 448 
personalized medical management. 449 
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 590 
Figure Legends 591 
Fig. 1: LH, FSH and testosterone values along with testicular volumes (largest testicle) at last 592 
evaluation according to age. Blue dots represent the genital group, green represent the non-593 
genital group. Solid lines are reference ranges (mean and ±2 SD for the hormones and mean, ±1 594 
SD and ±2 SD for testicular volumes). Dotted lines signify LODs. 595 
Fig. 2a: Height (cm) according to age stratified according to rhGH treatment and group. Red dots 596 
represent rhGH treatment, blue dots represent the genital group, green represent the non-genital. 597 
Solid lines represent WHO reference ranges (mean, ±1 SD and ±2 SD).  598 
Fig. 2b: Height and height according to genetic potential (height – target height) expressed in SD 599 
scores according to group and rhGH treatment. Dots represent patients in the genital group, red 600 
have received rhGH treatment, blue have not. Squares represent patients in the non-genital 601 
group, red have received rhGH treatment, blue have not. Solid lines represent group medians. 602 
Fig. 2c: Height SD scores according to rhGH treatment and stratified according to group. Red dots 603 
represent rhGH treatment, blue dots represent the genital group, green represent the non-genital. 604 
Dotted lines represent ±2 SD. 605 
Fig. 3: Key histology findings in terms of phenotype, presence of germ cells and germ cell 606 
differentiation counted by patients and gonads, respectively. 607 
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Fig. 4: The histological spectrum found in the gonadal samples from males with 45,X/46,XY 608 
mosaicism. All images show Haematoxylin Eosin stained sections. 609 
 610 
 611 
 612 
Table 1: Differences between the genital and non-genital group in terms of age, genital 613 
phenotype, growth, comorbidities, surgeries and gonadal neoplasia. 614 
Table 2: Histological findings in samples from 61 gonads grouped according to reason for diagnosis 615 
and including ages at the time of biopsy/gonadectomy and EMS scores. 616 
Table 3: Tally of patients with Sertoli cell only pattern alongside spermatocytic arrest, full 617 
spermatogenesis and/or GCNIS. 618 
Table 4: Reproductive hormones, clinical features and gonadal histology in patients with available 619 
semen analyses. 620 
